JP7249951B2 - 標的臓器の細胞外構成成分を使用する治療用細胞の作製 - Google Patents

標的臓器の細胞外構成成分を使用する治療用細胞の作製 Download PDF

Info

Publication number
JP7249951B2
JP7249951B2 JP2019553818A JP2019553818A JP7249951B2 JP 7249951 B2 JP7249951 B2 JP 7249951B2 JP 2019553818 A JP2019553818 A JP 2019553818A JP 2019553818 A JP2019553818 A JP 2019553818A JP 7249951 B2 JP7249951 B2 JP 7249951B2
Authority
JP
Japan
Prior art keywords
macrophages
cells
tissue
specific
educated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019553818A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020511999A5 (https=
JP2020511999A (ja
Inventor
ペイマン ヘマッティ
エリック ジー シュムック
ジョン エイ キンク
アーミッシュ エヌ ラヴァル
Original Assignee
ウィスコンシン アラムニ リサーチ ファンデーション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ウィスコンシン アラムニ リサーチ ファンデーション filed Critical ウィスコンシン アラムニ リサーチ ファンデーション
Publication of JP2020511999A publication Critical patent/JP2020511999A/ja
Publication of JP2020511999A5 publication Critical patent/JP2020511999A5/ja
Priority to JP2022205718A priority Critical patent/JP7419490B2/ja
Application granted granted Critical
Publication of JP7249951B2 publication Critical patent/JP7249951B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0645—Macrophages, e.g. Kuepfer cells in the liver; Monocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/33—Fibroblasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/17—Monocytes; Macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22—Immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/416—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/418—Antigens related to induction of tolerance to non-self
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/70—Undefined extracts
    • C12N2500/80—Undefined extracts from animals
    • C12N2500/84—Undefined extracts from animals from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
    • C12N2502/1323—Adult fibroblasts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
    • C12N2502/1352—Mesenchymal stem cells
    • C12N2502/1358—Bone marrow mesenchymal stem cells (BM-MSC)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Microbiology (AREA)
  • Vascular Medicine (AREA)
  • Biochemistry (AREA)
  • Botany (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
JP2019553818A 2017-03-31 2018-03-30 標的臓器の細胞外構成成分を使用する治療用細胞の作製 Active JP7249951B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022205718A JP7419490B2 (ja) 2017-03-31 2022-12-22 標的臓器の細胞外構成成分を使用する治療用細胞の作製

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
NL2018628 2017-03-31
NL2018628 2017-03-31
PCT/US2018/025371 WO2018183825A1 (en) 2017-03-31 2018-03-30 Generation of therapeutic cells using extracellular components of target organs

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022205718A Division JP7419490B2 (ja) 2017-03-31 2022-12-22 標的臓器の細胞外構成成分を使用する治療用細胞の作製

Publications (3)

Publication Number Publication Date
JP2020511999A JP2020511999A (ja) 2020-04-23
JP2020511999A5 JP2020511999A5 (https=) 2021-05-06
JP7249951B2 true JP7249951B2 (ja) 2023-03-31

Family

ID=58548819

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019553818A Active JP7249951B2 (ja) 2017-03-31 2018-03-30 標的臓器の細胞外構成成分を使用する治療用細胞の作製
JP2022205718A Active JP7419490B2 (ja) 2017-03-31 2022-12-22 標的臓器の細胞外構成成分を使用する治療用細胞の作製

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022205718A Active JP7419490B2 (ja) 2017-03-31 2022-12-22 標的臓器の細胞外構成成分を使用する治療用細胞の作製

Country Status (7)

Country Link
US (2) US11760975B2 (https=)
EP (1) EP3600354B1 (https=)
JP (2) JP7249951B2 (https=)
AU (1) AU2018243554C1 (https=)
CA (1) CA3058437A1 (https=)
DK (1) DK3600354T3 (https=)
WO (1) WO2018183825A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2949083C (en) 2014-05-18 2023-10-10 Children's Medical Center Corporation Methods and compositions relating to exosomes
US11738046B2 (en) 2017-11-03 2023-08-29 Wisconsin Alumni Research Foundation Macrophage cell therapy to treat orthopedic injury
US10876753B2 (en) 2018-02-12 2020-12-29 Watsco Ventures Llc Integrated sensor and service port for HVAC equipment or HVAC system
CN112334190B (zh) 2018-04-30 2024-09-20 儿童医学中心公司 间充质基质细胞外排体及其用途
CA3099042A1 (en) * 2018-05-09 2019-11-14 Children's Medical Center Corporation Mesenchymal stromal cell exosome -treated monocytes and uses thereof
US12350293B2 (en) 2019-03-08 2025-07-08 Niigata University Induction method for macrophage, anti-inflammatory macrophage-inducing agent, and pharmaceutical composition
US20230071393A1 (en) * 2020-04-16 2023-03-09 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Matrix bound vesicles (mbv) for treatment of acute respiratory distress syndrome
EP3984527A1 (en) 2020-10-13 2022-04-20 Ludwig-Maximilians-Universität München Nano-in-micro encapsulated sirna dry powder, method for producing the same and use of a powder formulation as a pharmaceutical dosage form, in particular for pulmonary delivery
US20220127579A1 (en) * 2020-10-22 2022-04-28 Wisconsin Alumni Research Foundation Use of Toll-Like Receptor 4 Agonists to Treat Inflammation and Tissue Injury
WO2023003775A2 (en) * 2021-07-21 2023-01-26 The Regents Of The University Of California Human ipsc-derived macrophages for liver repair and regeneration
EP4398948A4 (en) * 2021-09-07 2025-07-09 Wisconsin Alumni Res Found CARDIAC FIBROBLAST-DERIVED EXTRACELLULAR MATRIX

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110045071A1 (en) 2009-08-24 2011-02-24 Peiman Hematti Generation of a novel type of anti-inflammatory macrophages for clinical use
WO2015031376A1 (en) 2013-08-26 2015-03-05 The Trustees Of Columbia University In The City Of New York Scaffolds containing cytokines for tissue engineering
WO2015189063A1 (en) 2014-06-10 2015-12-17 Mesoblast International Sàrl Treatment of immune disorders

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2011013452A (es) * 2009-07-02 2012-04-30 Ith Immune Therapy Holdings Ab Tratamiento de cancer basado en exosomas.
US8802144B2 (en) 2011-08-25 2014-08-12 Wisconsin Alumni Research Foundation 3-dimensional cardiac fibroblast derived extracellular matrix
US10166254B2 (en) 2014-09-19 2019-01-01 Wisconsin Alumni Research Foundation Use of mesenchymal stem cell-educated macrophages to treat and prevent graft versus host disease and radiation-induced injury
EP3204117A4 (en) * 2014-10-06 2018-05-09 Cedars-Sinai Medical Center Polarization of macrophages to a healing phenotype by cardiosphere-derived cells and by the exosomes secreted by such cells
KR20180015187A (ko) 2015-06-03 2018-02-12 위스콘신 얼럼나이 리서어치 화운데이션 심장 섬유모세포-유래된 세포외 기질 및 허혈성 질환 또는 손상의 치료를 위한 이의 주사 가능한 제형
US11738046B2 (en) 2017-11-03 2023-08-29 Wisconsin Alumni Research Foundation Macrophage cell therapy to treat orthopedic injury

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110045071A1 (en) 2009-08-24 2011-02-24 Peiman Hematti Generation of a novel type of anti-inflammatory macrophages for clinical use
WO2015031376A1 (en) 2013-08-26 2015-03-05 The Trustees Of Columbia University In The City Of New York Scaffolds containing cytokines for tissue engineering
WO2015189063A1 (en) 2014-06-10 2015-12-17 Mesoblast International Sàrl Treatment of immune disorders

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
J. Clin. Invest.，Vol.126, No.6，2016年06月，pp.2151-2166
J. Mol. Cell. Cardiol.，2016年，Vol.101，pp.69-80
Neural. Regen. Res.，2016年04月，Vol.11, No.4，pp.554-556

Also Published As

Publication number Publication date
WO2018183825A1 (en) 2018-10-04
DK3600354T3 (da) 2023-10-30
US20230407256A1 (en) 2023-12-21
EP3600354A1 (en) 2020-02-05
JP2023052043A (ja) 2023-04-11
AU2018243554B2 (en) 2024-02-15
JP2020511999A (ja) 2020-04-23
AU2018243554A1 (en) 2019-10-17
CA3058437A1 (en) 2018-10-04
US11760975B2 (en) 2023-09-19
EP3600354B1 (en) 2023-09-20
US20180282698A1 (en) 2018-10-04
JP7419490B2 (ja) 2024-01-22
AU2018243554C1 (en) 2025-01-30

Similar Documents

Publication Publication Date Title
JP7419490B2 (ja) 標的臓器の細胞外構成成分を使用する治療用細胞の作製
Nasef et al. Leukemia inhibitory factor: Role in human mesenchymal stem cells mediated immunosuppression
US9877989B2 (en) Use of preparations comprising exosomes derived from mesenchymal stem cells (MSCs) in the prevention and therapy of inflammatory conditions
Rieger et al. Mesenchymal stem cells remain of host origin even a long time after allogeneic peripheral blood stem cell or bone marrow transplantation
CA2747207C (en) Pharmaceutical preparations for treating internal inflammatory conditions, and methods of preparing same
US20220349599A1 (en) LPS Priming of Stromal Cells to Generate LPS-Specific Exosome Educated Macrophages
JP2020500008A (ja) 免疫疾患の治療のための高効能幹細胞の選別方法
KR20180100250A (ko) 양막 유래 부착성 세포를 사용한, 면역-관련 질환 및 장애의 치료
Kolanko et al. Increased immunomodulatory capacity of human amniotic cells after activation by pro-inflammatory chemokines
JP2024515690A (ja) 疾患の治療のための間葉系間質細胞からの細胞外小胞
WO2015076717A2 (en) Mscs in the treatment of cardiac disorders
Tournois et al. Cell therapy in critical limb ischemia: a comprehensive analysis of two cell therapy products
JP2024516173A (ja) 間葉系前駆体又は幹細胞を使用する特定の患者における急性呼吸窮迫症候群（ａｒｄｓ）を治療するための方法
JP2022551103A (ja) 骨髄間葉系幹細胞由来細胞集団およびその調製方法
Rawat et al. A comparative study on immunomodulatory potential of tissue specific hMSCs: Role of HLA-G
US11963983B2 (en) Methods of cardiac repair
US20230149523A1 (en) Treatment of autoimmunity and transplant rejection through establishment and/or promotion of tolerogenic processes by fibroblast-mediated reprogramming of antigen presenting cells
US20170246210A1 (en) Ex-vivo induced regulatory mesenchymal stem cells or myeloid-derived suppressor cells as immune modulators
US20200038451A1 (en) Stem cells as an individualized maternal therapy for prevention of prematurity
Cantilena The Role of Endoglin in the Immunomodulatory Capacities of Mesenchymal Stem Cells and the Relationship to Hyperbaric Oxygen Therapy
Rojphaisarn Isolation and characterization of mesenchymal stem cells from umbilical cord, placenta and amnion

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210329

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210329

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20211216

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220111

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220411

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220822

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221222

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20221222

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20230105

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20230207

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20230208

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230306

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230320

R150 Certificate of patent or registration of utility model

Ref document number: 7249951

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250